AbstractBackgroundRisk estimates for proven non-carriers in BRCA mutation families are inconsistent for breast cancer and lacking for ovarian cancer. We aimed to assess the age-related risks for breast and ovarian cancer for proven non-carriers in these families.MethodsA consecutive cohort study ascertained 464 proven non-carriers who had a first-degree relative with a pathogenic BRCA mutation. Kaplan–Meier analyses were used to estimate the age-related cancer risks, and we calculated standardised incidence ratios.ResultsIn the 464 non-carriers, 17 breast cancers and two ovarian cancers were detected at a mean age of 47 years (95% confidence interval (CI) 32–61) and 49 years (95% CI 32–67), respectively. Overall, by the age of 50, the breas...
Background: BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks ...
Accurate estimations of lifetime risks of breast and ovarian cancer are crucial for counselling wome...
Accurate estimations of lifetime risks of breast and ovarian cancer are crucial for counselling wome...
AbstractBackgroundRisk estimates for proven non-carriers in BRCA mutation families are inconsistent ...
Background: Risk estimates for proven non-carriers in BRCA mutation families are inconsistent for br...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospecti...
BACKGROUND: In BRCA2 mutation carriers, increased risks have been reported for several cancer sites ...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospect...
Background: BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks ...
Accurate estimations of lifetime risks of breast and ovarian cancer are crucial for counselling wome...
Accurate estimations of lifetime risks of breast and ovarian cancer are crucial for counselling wome...
AbstractBackgroundRisk estimates for proven non-carriers in BRCA mutation families are inconsistent ...
Background: Risk estimates for proven non-carriers in BRCA mutation families are inconsistent for br...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospecti...
BACKGROUND: In BRCA2 mutation carriers, increased risks have been reported for several cancer sites ...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averag...
Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospect...
Background: BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks ...
Accurate estimations of lifetime risks of breast and ovarian cancer are crucial for counselling wome...
Accurate estimations of lifetime risks of breast and ovarian cancer are crucial for counselling wome...